Skip to main content
4D Molecular Therapeutics, Inc. logo

4D Molecular Therapeutics, Inc. — Investor Relations & Filings

Ticker · FDMT ISIN · US35104E1001 US Manufacturing
Open in API
Filings indexed 372 across all filing types
Latest filing 2020-12-17 Director's Dealing
Country US United States of America
Listing US FDMT

About 4D Molecular Therapeutics, Inc.

https://4dmoleculartherapeutics.com/

4D Molecular Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on inventing and developing genetic medicines to treat large-market diseases with unmet medical needs. The company utilizes its proprietary Therapeutic Vector Evolution platform, which harnesses the power of directed evolution, to create customized and optimized adeno-associated virus (AAV) vectors. These engineered vectors are designed for targeted delivery and enhanced therapeutic efficacy. 4DMT's clinical pipeline is concentrated on developing transformative products for serious conditions in ophthalmology, such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), and in pulmonology, including cystic fibrosis.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2020-12-17 English
FORM 3/A
Director's Dealing
2020-12-17 English
S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used for registering securities to be offered under employee benefit plans such as equity incentive plans and employee stock purchase plans. It includes detailed information about the securities to be registered, the plans under which they are offered, indemnification provisions, and exhibits related to corporate governance documents and legal opinions. This type of filing is a registration statement for securities issuance and does not fit into categories like Annual Report, Earnings Release, or Capital/Financing Update. The Form S-8 is a specific SEC registration form for employee benefit plans and is not a financial report or announcement of voting results. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a regulatory filing that does not fit into other specific categories.
2020-12-15 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes amendments to the company's articles of incorporation and bylaws, details about the initial public offering (IPO) completion, and related corporate governance changes. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or quarterly reports. It also does not fit into categories like earnings release, management reports, or audit reports. The document is an announcement of significant corporate events and changes, which aligns with the Regulatory Filings (RNS) category, a fallback for miscellaneous filings that do not fit other specific categories. The document length (7372 characters) and content confirm it is a full filing, not just a brief announcement of a report publication.
2020-12-15 English
424B4
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus for an initial public offering (IPO) of common stock by 4D Molecular Therapeutics, Inc. It includes extensive information typical of an IPO prospectus such as risk factors, use of proceeds, dividend policy, capitalization, dilution, selected financial data, management discussion and analysis, business overview, management, executive compensation, principal stockholders, description of capital stock, underwriting, legal matters, and financial statements. The presence of underwriting details, offering price, number of shares, and SEC registration number (Rule 424(b)(4)) confirms this is a registration/prospectus document related to capital raising. This type of document is best classified under Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes. It is not an annual report, earnings release, or other report type, but a financing prospectus for an IPO.
2020-12-12 English
Regulatory Filings 2020
Regulatory Filings
2020-12-11 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.